Hemogenyx Pharmaceuticals annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals Capital Expenditures (CapEx) Growth & History (HEMO)
Hemogenyx Pharmaceuticals's capital expenditures (capex) was £3,921 for fiscal 2025.
View full Hemogenyx Pharmaceuticals company overviewHemogenyx Pharmaceuticals annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £3,921 | −£9,364 | −70.49% |
| 2024 | 2024-12-31 | £13,285 | −£104,000 | −88.67% |
| 2023 | 2023-12-31 | £117,285 | −£311,660 | −72.66% |
| 2022 | 2022-12-31 | £428,945 | −£207,310 | −32.58% |
| 2021 | 2021-12-31 | £636,255 | £463,208 | +267.68% |
| 2020 | 2020-12-31 | £173,047 | — | — |
Hemogenyx Pharmaceuticals capital expenditures (capex) trends
Over the last five fiscal years, Hemogenyx Pharmaceuticals's capital expenditures (capex) decreased from £173,047 to £3,921, a change of −£169,126.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company official filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hemogenyx Pharmaceuticals source filings ↗